search
Back to results

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease (PRINCE)

Primary Purpose

Crohn's Disease

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
PRV-6527
Placebo
Sponsored by
Provention Bio, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Crohn's Disease focused on measuring Crohn's Disease

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject must be a man or woman between 18 years and 75 (inclusive) years of age.
  2. Has moderate to severe CD and a histologic diagnosis of CD for at least 3 months before screening.

Exclusion Criteria:

  1. Has other gastrointestinal inflammatory diseases.
  2. Has any malignancy or lymphoproliferative disorder other than nonmelanoma cutaneous malignancies or cervical carcinoma in situ that has been treated with no evidence of recurrence.
  3. Has colon cancer or severe dysplasia. Subjects with CD for ≥8 years involving the colon are not excluded if they had a colonoscopy to assess for the presence of dysplasia within 1 year before baseline or if they had a colonoscopy at the screening visit that excludes any evidence of malignancy.
  4. Has current signs or symptoms of an acute infection or infected skin wounds or ulcers, with the exception of nonserious infections in the opinion of the Investigator (e.g. sepsis, pneumonia, or pyelonephritis), including any infection requiring hospitalization or IV antibiotics, within 8 weeks before baseline.
  5. Has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms thereof.
  6. Has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

Sites / Locations

  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site2
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site2
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site2
  • Clinical site
  • Clinical Site
  • Clinical site
  • Clinical Site
  • Clinical Site2
  • Clinical Site
  • Clinical Site
  • Clinical site
  • Clinical Site
  • Clinical Site2
  • Clinical Site
  • Clinical Site
  • ClinicaL Site
  • Clinical Site
  • Clinical Site 2
  • Clinical Site
  • Clinical Site
  • Clinical site
  • Clinical Site 3
  • Clinical Site2
  • Clinical Site
  • Clinical Site2
  • Clinical Site
  • Clinical Site
  • Clinical Site
  • Clinical Site2
  • Clinical Site3
  • Clinical Site
  • Clinical Site2
  • Clinical Site3
  • Clinical Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

PRV-6527

Placebo

Arm Description

Oral administration, 2X daily for 12 weeks

Oral administration, 2X daily for 12 weeks

Outcomes

Primary Outcome Measures

Change from baseline to Week 12 in Crohn's Disease Activity Index score
Crohn's Disease Activity Scale will be assessed by collecting information on 8 different Crohn's Disease-related variables : extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stood, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being. The last 4 variable are based on dairy of patient for 7 days Scale range is 0 to 600 with 0 being the best oputcome and a score of 600, the worst outcome.

Secondary Outcome Measures

Full Information

First Posted
February 23, 2019
Last Updated
September 14, 2021
Sponsor
Provention Bio, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03854305
Brief Title
Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease
Acronym
PRINCE
Official Title
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of CSF-1 Receptor, in Subjects With Moderately to Severely Active Crohn's
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
March 20, 2018 (Actual)
Primary Completion Date
August 13, 2019 (Actual)
Study Completion Date
August 13, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Provention Bio, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will evaluate the efficacy and safety of oral PRV-6527 in the treatment of moderately to severely active Crohn's disease
Detailed Description
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with moderately to severely active Crohn's disease. Eligible subjects include males and females aged 18-75 years with moderately to severely active CD for at least 3 months. Each subject will receive the assigned treatment over 12 weeks, followed by a 4-week safety follow-up period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn's Disease
Keywords
Crohn's Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
93 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PRV-6527
Arm Type
Experimental
Arm Description
Oral administration, 2X daily for 12 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Oral administration, 2X daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
PRV-6527
Intervention Description
Treatment
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Comparator
Primary Outcome Measure Information:
Title
Change from baseline to Week 12 in Crohn's Disease Activity Index score
Description
Crohn's Disease Activity Scale will be assessed by collecting information on 8 different Crohn's Disease-related variables : extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stood, abdominal pain/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being. The last 4 variable are based on dairy of patient for 7 days Scale range is 0 to 600 with 0 being the best oputcome and a score of 600, the worst outcome.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject must be a man or woman between 18 years and 75 (inclusive) years of age. Has moderate to severe CD and a histologic diagnosis of CD for at least 3 months before screening. Exclusion Criteria: Has other gastrointestinal inflammatory diseases. Has any malignancy or lymphoproliferative disorder other than nonmelanoma cutaneous malignancies or cervical carcinoma in situ that has been treated with no evidence of recurrence. Has colon cancer or severe dysplasia. Subjects with CD for ≥8 years involving the colon are not excluded if they had a colonoscopy to assess for the presence of dysplasia within 1 year before baseline or if they had a colonoscopy at the screening visit that excludes any evidence of malignancy. Has current signs or symptoms of an acute infection or infected skin wounds or ulcers, with the exception of nonserious infections in the opinion of the Investigator (e.g. sepsis, pneumonia, or pyelonephritis), including any infection requiring hospitalization or IV antibiotics, within 8 weeks before baseline. Has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms thereof. Has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Provention Bio, MD
Organizational Affiliation
Provention Bio
Official's Role
Study Director
Facility Information:
Facility Name
Clinical Site
City
Innsbruck
Country
Austria
Facility Name
Clinical Site
City
Klagenfurt am Wörthersee
Country
Austria
Facility Name
Clinical Site
City
St. Polten
Country
Austria
Facility Name
Clinical Site
City
St. Veit an der Glan
Country
Austria
Facility Name
Clinical Site
City
Vienna
Country
Austria
Facility Name
Clinical Site
City
Berlin
Country
Germany
Facility Name
Clinical Site
City
Hamburg
Country
Germany
Facility Name
Clinical Site
City
Kiel
Country
Germany
Facility Name
Clinical Site
City
Landshut
Country
Germany
Facility Name
Clinical Site
City
Ulm
Country
Germany
Facility Name
Clinical Site2
City
Budapest
Country
Hungary
Facility Name
Clinical Site
City
Budapest
Country
Hungary
Facility Name
Clinical Site
City
Miskolc
Country
Hungary
Facility Name
Clinical Site
City
Mosonmagyaróvár
Country
Hungary
Facility Name
Clinical Site
City
Bydgoszcz
Country
Poland
Facility Name
Clinical Site2
City
Kraków
Country
Poland
Facility Name
Clinical Site
City
Kraków
Country
Poland
Facility Name
Clinical Site
City
Piotrków Trybunalski
Country
Poland
Facility Name
Clinical Site
City
Warszawa
Country
Poland
Facility Name
Clinical Site2
City
Wrocław
Country
Poland
Facility Name
Clinical site
City
Wrocław
Country
Poland
Facility Name
Clinical Site
City
Łódź
Country
Poland
Facility Name
Clinical site
City
Kemerovo
Country
Russian Federation
Facility Name
Clinical Site
City
Krasnoyarsk
Country
Russian Federation
Facility Name
Clinical Site2
City
Moscow
Country
Russian Federation
Facility Name
Clinical Site
City
Moscow
Country
Russian Federation
Facility Name
Clinical Site
City
Penza
Country
Russian Federation
Facility Name
Clinical site
City
Rostov-on-Don
Country
Russian Federation
Facility Name
Clinical Site
City
Saint Petersburg
Country
Russian Federation
Facility Name
Clinical Site2
City
Samara
Country
Russian Federation
Facility Name
Clinical Site
City
Samara
Country
Russian Federation
Facility Name
Clinical Site
City
Tomsk
Country
Russian Federation
Facility Name
ClinicaL Site
City
Cordoba
Country
Spain
Facility Name
Clinical Site
City
Girona
Country
Spain
Facility Name
Clinical Site 2
City
Madrid
Country
Spain
Facility Name
Clinical Site
City
Madrid
Country
Spain
Facility Name
Clinical Site
City
Kharkiv
Country
Ukraine
Facility Name
Clinical site
City
Khmelnytskyi
Country
Ukraine
Facility Name
Clinical Site 3
City
Kyiv
Country
Ukraine
Facility Name
Clinical Site2
City
Kyiv
Country
Ukraine
Facility Name
Clinical Site
City
Kyiv
Country
Ukraine
Facility Name
Clinical Site2
City
Lviv
Country
Ukraine
Facility Name
Clinical Site
City
Lviv
Country
Ukraine
Facility Name
Clinical Site
City
Odesa
Country
Ukraine
Facility Name
Clinical Site
City
Ternopil'
Country
Ukraine
Facility Name
Clinical Site2
City
Vinnytsia
Country
Ukraine
Facility Name
Clinical Site3
City
Vinnytsia
Country
Ukraine
Facility Name
Clinical Site
City
Vinnytsia
Country
Ukraine
Facility Name
Clinical Site2
City
Zaporizhzhya
Country
Ukraine
Facility Name
Clinical Site3
City
Zaporizhzhya
Country
Ukraine
Facility Name
Clinical Site
City
Zaporizhzhya
Country
Ukraine

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease

We'll reach out to this number within 24 hrs